Caplin Point Laboratories
Caplin Point Laboratories Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Caplin Point Laboratories
Start SIPCaplin Point Laboratories Investment Rating
-
Master Rating:
-
Caplin Point Labs. has an operating revenue of Rs. 1,466.73 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 31% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 6% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 11% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 53 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 103 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 145 | 131 | 137 | 116 | 112 |
| Operating Expenses Qtr Cr | 80 | 79 | 80 | 70 | 74 |
| Operating Profit Qtr Cr | 65 | 52 | 57 | 46 | 38 |
| Depreciation Qtr Cr | 6 | 6 | 7 | 6 | 7 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 16 | 15 | 16 | 11 | 13 |
| Net Profit Qtr Cr | 54 | 59 | 58 | 63 | 29 |
Caplin Point Laboratories Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹721.52
- 50 Day
- ₹693.19
- 100 Day
- ₹689.06
- 200 Day
- ₹701.49
- 20 Day
- ₹718.71
- 50 Day
- ₹668.75
- 100 Day
- ₹676.94
- 200 Day
- ₹710.21
Caplin Point Laboratories Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹777.55 |
| Second Resistance | ₹798.35 |
| Third Resistance | ₹814.5 |
| RSI | 76.87 |
| MFI | 80.52 |
| MACD Single Line | 20.53 |
| MACD | 22.99 |
| Support | |
|---|---|
| First Resistance | ₹740.6 |
| Second Resistance | ₹724.45 |
| Third Resistance | ₹703.65 |
Caplin Point Laboratories Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 268,422 | 6,562,918 | 24.45 |
| Week | 136,687 | 5,410,064 | 39.58 |
| 1 Month | 95,622 | 3,973,081 | 41.55 |
| 6 Month | 83,228 | 3,639,551 | 43.73 |
Caplin Point Laboratories Result Highlights
Caplin Point Laboratories Synopsis
NSE-Medical-Generic Drugs
Caplin Point Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 528.61 Cr. and Equity Capital is Rs. 15.18 Cr. for the Year ended 31/03/2023. Caplin Point Laboratories Ltd. is a Public Limited Listed company incorporated on 16/04/1990 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24231TN1990PLC019053 and registration number is 019053.| Market Cap | 5,790 |
| Sales | 529 |
| Shares in Float | 2.20 |
| No of funds | 77 |
| Yield | 0.53 |
| Book Value | 5.04 |
| U/D Vol ratio | 1.7 |
| LTDebt / Equity | |
| Alpha | |
| Beta | 0.76 |
Caplin Point Laboratories
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 70.66% | 68.8% | 68.88% | 68.88% |
| Mutual Funds | 0.57% | 1.04% | 1.05% | 1.06% |
| Foreign Portfolio Investors | 2.36% | 2.24% | 2.15% | 2.03% |
| Financial Institutions/ Banks | ||||
| Individual Investors | 18.73% | 18.91% | 19% | 20.77% |
| Others | 7.68% | 9.01% | 8.92% | 7.26% |
Caplin Point Laboratories Management
| Name | Designation |
|---|---|
| Mr. C C Paarthipan | Chairman |
| Dr. Sridhar Ganesan | Managing Director |
| Mr. V Thirumalai | Independent Director |
| Mr. R Viswanathan | Independent Director |
| Mr. D Sathyanarayanan | Independent Director |
| Dr. C K Gariyali | Independent Director |
Caplin Point Laboratories Forecast
Price Estimates
Caplin Point Laboratories Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-27 | Audited Results & Interim Dividend | (Revised) per share(100%)Dividend |
| 2023-02-11 | Quarterly Results | |
| 2022-11-12 | Quarterly Results | |
| 2022-08-05 | Quarterly Results & Final Dividend | |
| 2022-05-12 | Audited Results & Interim Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2023-06-09 | FINAL | Rs.2.00 per share(100%)Interim Dividend |
| 2022-05-24 | INTERIM | Rs.2.00 per share(100%)Interim Dividend |
| 2021-05-19 | INTERIM | Rs.1.50 per share(75%)Interim Dividend |
Caplin Point Laboratories FAQs
What is Share Price of Caplin Point Laboratories ?
Caplin Point Laboratories share price is ₹761 As on 02 June, 2023 | 18:18
What is the Market Cap of Caplin Point Laboratories ?
The Market Cap of Caplin Point Laboratories is ₹5781.4 Cr As on 02 June, 2023 | 18:18
What is the P/E ratio of Caplin Point Laboratories ?
The P/E ratio of Caplin Point Laboratories is 15.4 As on 02 June, 2023 | 18:18
What is the PB ratio of Caplin Point Laboratories ?
The PB ratio of Caplin Point Laboratories is 3 As on 02 June, 2023 | 18:18